Antibody-DM1 conjugates as cancer therapeutics. - Wikidata - wikimedia - TriplyDB

Antibody-DM1 conjugates as cancer therapeutics.

Antibody-DM1 conjugates as cancer therapeutics.

http://www.wikidata.org/entity/Q34177359

about

Safety and Efficacy of Trastuzumab Emtansine in Advanced Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: a Meta-analysis.A mechanistic pharmacokinetic model elucidating the disposition of trastuzumab emtansine (T-DM1), an antibody-drug conjugate (ADC) for treatment of metastatic breast cancer.Design, synthesis and biological evaluation of di-substituted noscapine analogs as potent and microtubule-targeted anticancer agents Preclinical studies of a Pro-antibody-drug conjugate designed to selectively target EGFR-overexpressing tumors with improved therapeutic efficacy.Recent advances in the application of antibodies as therapeutics.Optimising the delivery of tubulin targeting agents through antibody conjugation.Immunoconjugates and long circulating systems: origins, current state of the art and future directions Modeling the effects of drug binding on the dynamic instability of microtubules

P2860

Q33430735-7B120A55-A349-4532-97F5-A590DB2CB563 Q34099745-20AF7E54-F3F0-49FA-A70D-50CCA4820F46 Q35737288-33F2B7ED-D91F-4474-ADF2-A4ACC39C316E Q37138420-AD4CB801-D86A-42D8-A50D-C5D86B109100 Q37968255-5C51F7C9-F889-41D7-97C7-1839071B26F0 Q38024991-1F453BE1-6F02-459A-8541-12D689238E74 Q38042256-BBF37E06-9A6E-471F-BBE2-8F11DB3FEE85 Q38341603-E760FB52-F5D8-4D66-8FFC-020DF373C8AF

P2860

Antibody-DM1 conjugates as cancer therapeutics.

http://www.wikidata.org/entity/Q34177359

description

2011 nî lūn-bûn

@nan

2011 թուականի Ապրիլին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի ապրիլին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

name

Antibody-DM1 conjugates as cancer therapeutics.

@ast

Antibody-DM1 conjugates as cancer therapeutics.

@en

Antibody-DM1 conjugates as cancer therapeutics.

@nl

type

label

Antibody-DM1 conjugates as cancer therapeutics.

@ast

Antibody-DM1 conjugates as cancer therapeutics.

@en

Antibody-DM1 conjugates as cancer therapeutics.

@nl

prefLabel

Antibody-DM1 conjugates as cancer therapeutics.

@ast

Antibody-DM1 conjugates as cancer therapeutics.

@en

Antibody-DM1 conjugates as cancer therapeutics.

@nl

P1433

Q34177359-12FAF927-9AEF-4A1D-B0D1-546F65A6014F

P1476

Q34177359-3052AFCA-E1EB-4901-A844-891C1967F067

P2093

Q34177359-43BDBFE0-C909-44B4-9C3A-0433594C31D0

P2860

Q34177359-167A3EDF-42CD-445B-80E6-17A2AB5FDA8B

Q34177359-1CA0AA3B-5249-43DB-AAB8-3CEF3E7D8AE6

Q34177359-288C3C70-7E8D-4F2F-A2DA-030BE246149E

Q34177359-2EEE4C6F-9F5A-4F17-A2FD-20B101EAFDB5

Q34177359-3452875D-CF19-4D3C-8B43-47DF3F972544

Q34177359-3B20CBA1-47D1-4872-B04C-AC3CC1826CC1

Q34177359-400E6DBC-3F7B-4769-A7D3-FD6ABD959252

Q34177359-4346986F-7E38-4D9A-B8CD-1C631B672793

Q34177359-516EBE1A-EDFE-4AF2-8B90-DF6E51BC68BB

Q34177359-5429BFDF-2AF2-47DE-91DA-037820592408

P304

Q34177359-2D7629DC-5241-426B-A0E7-D959327330DC

P31

Q34177359-8C7D0153-6A6C-49B7-95F3-2BD89E9F86DF

P356

Q34177359-76F6A6D8-D786-4D38-A04E-370AA5C79DA1

P407

Q34177359-69FBC82C-011A-40F0-9F3D-DB4AD82CB51C

P433

Q34177359-121077F8-F8D4-4F8F-937D-6504481BA231

P478

Q34177359-F9323256-1988-49BE-B79E-02EBC81EBAE8

P50

Q34177359-C2C2C8A7-E108-4A3D-9884-70B0BFDACA95

P577

Q34177359-E6BB3025-90E5-4FDC-BAA4-7D8C9A50ED8E

P5875

Q34177359-7817E5D5-4A8E-497A-BE58-5BD8AE43D85B

P698

Q34177359-3C21CAE5-D13D-4270-AC82-3D44FA218093

P921

Q34177359-79FC5FA9-4748-47D6-A59B-01DCF5F769E0

P932

Q34177359-001B0D4E-D264-4565-A80B-29E56732FFC8

P356

J.CANLET.2011.03.017

P1433

P1476

Antibody-DM1 conjugates as cancer therapeutics

@en

P2093

Manu Lopus

http://www.w3.org/2001/XMLSchema#string

P2860

Ep-CAM: a human epithelial antigen is a homophilic cell-cell adhesion molecule

Microtubule-binding agents: a dynamic field of cancer therapeutics.

Cantuzumab mertansine, a maytansinoid immunoconjugate directed to the CanAg antigen: a phase I, pharmacokinetic, and biologic correlative study

Microtubules as a target for anticancer drugs

Trastuzumab--mechanism of action and use in clinical practice

Maytansine and cellular metabolites of antibody-maytansinoid conjugates strongly suppress microtubule dynamics by binding to microtubules

A molecular and structural mechanism for G protein-mediated microtubule destabilization.

Phase II study of maytansine in the treatment of advanced or recurrent squamous cell carcinoma of the cervix. A Gynecologic Oncology Group study.

Analysis of dynamic instability of steady-state microtubules in vitro by video-enhanced differential interference contrast microscopy with an appendix by Emin Oroudjev.

Trastuzumab, a recombinant DNA-derived humanized monoclonal antibody, a novel agent for the treatment of metastatic breast cancer.

P304

113-118

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.CANLET.2011.03.017

http://www.w3.org/2001/XMLSchema#string

P407

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

307

http://www.w3.org/2001/XMLSchema#string

P50

P577

2011-04-09T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

51040360

http://www.w3.org/2001/XMLSchema#string

P698

21481526

http://www.w3.org/2001/XMLSchema#string

P921

P932

3105156

http://www.w3.org/2001/XMLSchema#string